Funded Projects › H2020
PIONEER · Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope
Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such as insufficient knowledge on risk factors that contribute to PCa and on patient characteristics (including genetic profiles) that could facilitate patient stratification. Finally, there is lack of meaningful engagement of all key stakeholders, while the knowledge currently gained from clinical practice and real life data is not being fed back into PCa patients’ care pathways. There is thus a need for better definition of PCa across all stages, improved patient’s stratification at diagnosis, and standardisation of PCa-related outcomes based on real life data.PIONEER’s unique dual approach is to first identify critical evidence gaps in PCa by respected Key Opinion Leaders, and then embark on a research priority setting exercise that reflects the needs of all key stakeholders in PCa management. To achieve this, PIONEER has brought together comprehensive datasets that consists of the most relevant prostate clinical trials and registries, large epidemiological cohorts, electronic heath records, and real-life data from different European (and non-European) patient populations. These unique data sets will be integrated, standardised, harmonised and analysed using approaches that are built on our experience of similar previous IMI projects i.e EMIF, and eTRIKS, and analysed using a unique set of methodologies and advanced analytics methods (OMOP, eHS). PIONEER has already performed a first PCa research priority setting survey, where major stakeholders were asked to identify the current unmet needs in PCa. The five most important open questions will be used as pilot studies to verify PIONEER’s research framework. As such, PIONEER’s deliverables will be outcome-driven, value-based and patient-centric, and relevant to all key stakeholders, as they would have been meaningfully involved from the inception of the project.
Consortium · 34 organisations
STICHTING EUROPEAN UROLOGICAL FOUNDATION
NL · €797,439
THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
UK · €409,303
NV SAS INSTITUTE SA
BE
PNO Life Sciences & Health B.V.
NL · €237,500
INTERNATIONAL CONSORTIUM FOR HEALTHOUTCOMES MEASUREMENT LTD
UK · €31,250
European Alliance for Personalised Medicine
SI · €180,000
LUNDS UNIVERSITET
SE · €185,761
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
UK · €200,000
WEIZMANN INSTITUTE OF SCIENCE
IL · €200,000
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
BE · €16,000
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
DE · €125,000
ASTRAZENECA AB
SE
THE ECANCER GLOBAL FOUNDATION
UK · €37,333
IHE, INSTITUTET FOR HALSO- OCH SJUKVARDSEKONOMI AKTIEBOLAG
SE · €175,000
ORION OYJ
FI
THE HYVE BV
NL · €400,000
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
NL · €124,922
IMS INFORMATION SOLUTIONS MEDICAL RESEARCH LIMITED
UK
TAMPEREEN KORKEAKOULUSAATIO SR
FI · €212,500
ASTELLAS PHARMA EUROPE BV
NL
EUROPEAN CANCER PATIENT COALITION
BE · €69,994
PINSENT MASONS LLP
UK · €188,800
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
DE · €150,000
BAYER AKTIENGESELLSCHAFT
DE
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
NL · €415,349
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
FR
ASSOCIATION EISBM
FR · €758,200
GOETEBORGS UNIVERSITET
SE · €150,650
HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV
DE · €101,300
LABCORP EARLY DEVELOPMENT LABORATORIES LIMITED
UK
JANSSEN PHARMACEUTICA NV
BE
KING'S COLLEGE LONDON
UK · €359,000
UNIVERSITA VITA-SALUTE SAN RAFFAELE
IT · €312,500
TECHNISCHE UNIVERSITAET DRESDEN
DE · €125,000
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.